Offman Elliot, Davidson Michael, Abu-Rashid Mohammad, Chai Peng, Nilsson Catarina
Clinical Pharmacology and Pharmacometrics, Celerion, 100 Boulevard Alexis-Nihon, Bureau (Suite) 360, Montreal, QC, H4M 2N8, Canada.
Department of Cardiology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):815-825. doi: 10.1007/s13318-016-0398-2.
Omega-3 carboxylic acids (OM3-CA) contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in free fatty acid form. Per gram, OM3-CA includes approximately half as much EPA as icosapent ethyl (IPE), an ethyl ester formulation of EPA.
The study aim was to assess systemic EPA and EPA + DHA exposures and plasma lipid parameters following multiple OM3-CA or IPE doses under low-fat dietary conditions, and dose proportionality after OM3-CA administration.
In this phase 1, two-cohort, open-label study (N = 114), participants following the Therapeutic Lifestyle Changes diet received either OM3-CA 2 g once daily for 10 days then OM3-CA 4 g once daily for 10 days, or IPE 2 g twice daily for 20 days. Exposure was considered similar if the 90% confidence intervals (CIs) of geometric least-squares mean (LSM) ratios for key pharmacokinetic parameters were within 80-125%.
Baseline-adjusted steady-state EPA exposure was similar after dosing with OM3-CA 4 g/day versus IPE 4 g/day (LSM ratio, area under the concentration-time curve from time 0 to 24 h: 93.9%; 90% CI 85.6, 103.0). Combined molar-equivalent EPA + DHA exposure was 30.6% higher following OM3-CA 4 g/day than IPE 4 g/day. EPA and DHA exposure increased approximately proportionally with OM3-CA dose (2-4 g/day). Changes from baseline in lipid parameters were similar in the two cohorts.
EPA exposure from OM3-CA and IPE was similar under low-fat dietary conditions, despite OM3-CA containing only approximately half as much EPA as IPE. EPA and DHA exposure from OM3-CA increased proportionally with dose.
ω-3羧酸(OM3-CA)以游离脂肪酸形式含有二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)。每克OM3-CA所含的EPA约为二十碳五烯酸乙酯(IPE,一种EPA的乙酯制剂)的一半。
本研究旨在评估在低脂饮食条件下多次服用OM3-CA或IPE后全身EPA及EPA+DHA暴露量和血浆脂质参数,以及服用OM3-CA后的剂量比例关系。
在这项1期、双队列、开放标签研究(N=114)中,遵循治疗性生活方式改变饮食的参与者接受以下两种方案之一:每天一次服用2克OM3-CA,共10天,然后每天一次服用4克OM3-CA,共10天;或每天两次服用2克IPE,共20天。如果关键药代动力学参数的几何最小二乘均值(LSM)比值的90%置信区间(CI)在80%-125%以内,则认为暴露量相似。
与每天服用4克IPE相比,每天服用4克OM3-CA后的基线调整稳态EPA暴露量相似(LSM比值,0至24小时浓度-时间曲线下面积:93.9%;90%CI 85.6,103.0)。每天服用4克OM3-CA后的总摩尔当量EPA+DHA暴露量比每天服用4克IPE高30.6%。EPA和DHA暴露量随OM3-CA剂量(2-4克/天)大致成比例增加。两个队列中脂质参数相对于基线的变化相似。
在低脂饮食条件下,OM3-CA和IPE的EPA暴露量相似,尽管OM3-CA所含的EPA仅约为IPE的一半。OM3-CA的EPA和DHA暴露量随剂量成比例增加。